Long-term treatment with Oleogel-S10 (birch bark extract, Filsuvez) gel significantly reduced wound burden and disease activity in individuals with epidermolysis bullosa (EB), with a high ...

Oleogel takes its inspiration from the food industry and uses a vegetable-based oil (like sesame oil), a gelling agent to achieve the desired viscosity and heat stability (like beeswax or candelilla ...

More than 41% of EB target wounds that were treated with Oleogel-S10 healed within 45 days, compared to about 29% of target wounds treated with placebo, in the EASE phase 3 trial, conducted at 58 ...

The oleogel system is composed of simple ingredients: a vegetable-based oil (such as cottonseed, safflower, or sesame oil), a gelling agent to optimize viscosity and heat-stability (such as beeswax, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has denied a New Drug Application for oleogel-S10 for the treatment of the cutaneous manifestations ...

Feb 28 - Amryt Pharma said on Monday the U.S. Food and Drug Administration declined to approve the company's drug for the treatment of a group of rare skin diseases called epidermolysis bullosa.

for Oleogel-S10 (Filsuvez®), for the treatment of the cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa (EB), a rare, genetic skin disease characterized by extremely ...

ADM (Archer Daniels Midland) – Exploring sustainable fat alternatives. BASF SE – Investing in pharmaceutical oleogel formulations. IOI Loders Croklaan – Innovating healthier alternatives to ...

The European Medicines Agency (“EMA”) review process for Oleogel-S10 in EB is ongoing and Amryt has responded to outstanding questions. Given the rarity of the disease without any approved ...